Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease
Open Access
- 1 January 1994
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 69 (1), 191-195
- https://doi.org/10.1038/bjc.1994.33
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of Clinical Oncology, 1992
- Epirubicin for pretreated advanced ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancerGynecologic Oncology, 1990
- Phase II Clinical Evaluation of Etoposide (VP-16-213, Vepesid®) as a Second-Line Treatment in Ovarian CancerOncology, 1990
- Doxorubicin and Cyclophosphamide, Alternated with Bleomycin and Mitomycin C as a Second-Line Regimen in Advanced Ovarian Carcinoma Resistant to Cisplatin-Based ChemotherapyOncology, 1990
- Hexamethylmelamine as a single second-line agent in ovarian cancerGynecologic Oncology, 1990
- Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignanciesGynecologic Oncology, 1986
- Variable bioavailability following repeated oral doses of etoposideEuropean Journal of Cancer and Clinical Oncology, 1985
- Phase II trial of VP-16-213 in advanced ovarian carcinomaGynecologic Oncology, 1985
- A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetryCancer Chemotherapy and Pharmacology, 1981